

# IMUGENE

AGM 2021

# Experienced Management Team with Significant Clinical Development Expertise

Imugene has a team with oncology clinical development experience



**Dr Rita Laeufle**

CALIFORNIA, USA

Chief Medical Officer

- 27+ years of oncology experience in academia and industry
- Clinical development experience with bevacizumab, trastuzumab, abrituzumab, CPIs and oncolytic viruses from Phase I – to post marketing Phase IV
- Former CMO at Oncolytics Biotech, Ex Genentech, Ex Hoffmann-La Roche, and Ex Novartis



**Dr Monil Shah**

NEW JERSEY, USA

Chief Business Officer

- 20+ years of oncology development experience in the pharmaceutical industry
- Former CDO at WindMIL, COO at Brooklyn ImmunoTherapeutics, and Head of Medical Affairs of ImmunoOncology at BMS
- Held senior roles at Novartis, Amgen, Fibrogen, and Celgene



**Dr Nick Ede**

MELBOURNE, AUS

Chief Technology Officer

- 25+ years peptide vaccine and drug development
- Former CEO Adistem and CEO of Mimotopes, VP Chemistry Chiron (now Novartis), Research Fellow CRC Vaccine Technology



**Dr Anthony Good**

SYDNEY, AUS

Senior VP of Clinical Research

- 20+ years experience in global clinical development
- Integral to the development of significant new medicines including Viagra®, Lipitor®, and Somavert®
- Ex Pfizer Global Research and Development, Ex Covance Clinical Services



**Amanda Seiz**

ILLINOIS, USA

Senior Director of Clinical Operations

- 20+ years experience in global drug development
- 16+ years of clinical operations leadership experience in oncology at CROs, pharmaceutical and biotechnology companies
- Development experience with small molecules, checkpoint inhibitors, gene/cellular therapies and oncolytic viruses
- Ex Head of Clinical Operations WindMIL Therapeutics, Ex Astellas Pharma, Ex MedImmune




**Bonnie Nixon**


SYDNEY, AUS

Senior Project Manager

- 10+ years of oncology clinical operations experience across Phase I – IV clinical trials
- Ex North America Study Manager at Genentech, Ex Roche Clinical Operations Australia

# Three Novel Technology Platforms





# 2021 YEAR IN REVIEW

## HER-Vaxx

- HERIZON: Phase 2 Interim Results with positive OS
- HERIZON: Enrollment Completed
- Presentations at AACR, ASCO and ESMO World GI
- HERIZON: PFS endpoint reached
- HER-Vaxx patent granted in Japan
- 3 New Phase 2 Gastric Studies: neoHERIZON, nextHERIZON and neuHERIZON
- neoHERIZON: Neoadjuvant study in combination with Avelumab with clinical drug supply partnership with Merck KGaA & Pfizer


**AACR** American Association  
for Cancer Research®

**ESMO** GOOD SCIENCE  
BETTER MEDICINE  
BEST PRACTICE


**WORLD CONGRESS ON  
Gastrointestinal  
Cancer**

**MERCK**

**Pfizer**








# 2021 YEAR IN REVIEW

## PD1-Vaxx

- PD1-Vaxx FDA IND granted in the USA
- IMPRINTER (Phase 1 Study): All 6 sites open in the USA and Australia
- Presentation at ESMO
- IMPRINTER (Phase 1 Study): Currently at the highest dose cohort






# 2021 YEAR IN REVIEW

## CHECKvacc

- CHECKvacc FDA IST IND granted in the USA
- Presentation at AACR
- CHECKvacc First Patient Dosed at COH



### Disease of need

- 8-13 month survival for metastatic disease with few treatments

### Potential target for immunotherapy


- Expresses PD1, PD-L1

### Treatment responses to Atezolizumab (JAMA Oncology, 5:74, 2019)

- 1st line: 24%;  
2nd line: 6%
- Approved by FDA  
8 March 2019

### Potential for registration in well-designed, randomised P2 study


Indication	TNBC
FDA IND	CHECKvacc: CF33-hNIS-aPDL1
N	Part 1=18-24 ; Part 2=12
Location	Single Center: COH
Admin Route	Intratumoral (IT)



## onCARlytics

- Licensed a CD19 oncolytic virus invented by Professor Yuman Fong and Dr Saul Priceman from City of Hope to turn CAR-T therapy against solid tumours
- Exclusive strategic partnership to combine onCARlytics with Celularity's allogeneic CAR-T, CyCART-19 immunotherapy for the treatment of solid tumors
- Strategic Collaboration to combine onCARlytics with Eureka Therapeutics ARTEMIS® T-Cell Therapy to accelerate therapy in solid tumours

# 2021 YEAR IN REVIEW



# 2021 Imugene Summary

**February  
2021**

PD1-Vaxx dose  
escalates to  
cohort 2

**June 2021**

CHECKvacc  
receives FDA IND



**July 2021**

\$95m Total  
Capital Raise  
& SPP

**September 2021**

S&P September  
Quarterly Re-balance  
Imugene enters  
ASX300



**November  
2021**

Strategic Partnership  
with Eureka



**May 2021**

Licensed onCARlytics  
from City of Hope  
invented by Dr Y Fong,  
Dr S Priceman &  
Dr A Park



**June 2021**

Appointment of Dr  
Monil Shah as the  
Chief Business  
Officer

**August  
2021**

Strategic  
Partnership with  
Celularity



**October  
2021**

CHECKvacc First  
Patient Dosed

**November 2021**

HER-Vaxx Clinical Trial  
Supply Partnership with  
Merck KGaA Pfizer





# Milestones

✓	Technology	Milestone
	onCARlytics	1 <sup>st</sup> Patient Dosed
	onCARlytics	FDA IND Clearance
	PD1-Vaxx	Combination RP2D
	onCARlytics	GLP Toxicology Study
	VAXINIA	1st Patient Dosed
	onCARlytics	FDA Pre-IND Meeting
	onCARlytics	GMP manufacturing for pre-clinical toxicology & Phase 1 study
	VAXINIA	FDA IND Clearance
	HER-Vaxx	Neo and Next HERIZON studies
	PD1-Vaxx	Maximum Feasible Dose Identified
	HER-Vaxx	OS Primary Endpoint
✓	HER-Vaxx	Clinical Trial Supply Partnership with Merck KGaA and Pfizer
✓	onCARlytics	Strategic Partnership with Eureka on autologous CD19 CART
✓	CHECKvacc	TNBC IST 1st Patient Dosed
✓	HER-Vaxx	PFS analysis data
✓	onCARlytics	Strategic partnership with Celularity on allogenic CD19 CART
✓	CHECKvacc	FDA IND Clearance

Next 12-24 months



# Financial Summary

## Public Market Overview (17/11/21)

Share Price	A\$0.54
52 week range	0.089 - 0.625
Market Capitalisation <sup>1</sup>	A\$3.063B
Cash equivalents (30 Sept 21)	A\$112.2M
Enterprise Value	A\$2.946B

## Top 5 Shareholders (as at November 2021)

Paul Hopper	6.96%
HSBC Custody Nominees (Australia)	5.98%
Richard Mann and Assoc.	5.35%
JP Morgan Nominees Australia Pty Limited	4.57%
Citicorp Nominees Pty Limited	3.67%

Note:

1. Market capitalisation calculations based on ordinary shares (5.673 bn) only and excludes the dilutive impact of options outstanding (0.558 bn)

## Share Price Performance (last 12 months)





ASX: IMU

IMUGENE LIMITED

[www.imugene.com](http://www.imugene.com)

[info@imugene.com](mailto:info@imugene.com)